Software Relating Genes to Disease and Clinical Outcomes

将基因与疾病和临床结果相关的软件

• 批准号: 6341382
• 负责人: Christophe G. Lambert
• 金额: $ 9.97万
• 依托单位: GOLDEN HELIX, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-01 至 2001-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6341382
• 关键词: computer data analysis; computer program /software; computer system design /evaluation; drug adverse effect; drug screening /evaluation; gene environment interaction; outcomes research; statistics /biometry

DESCRIPTION (Applicant's abstract): The development of a software system is proposed that will combine statistical theory, computer science algorithms, and genetics expertise to take advantage of the great influx of data generated by both the study of the human genome and the creation of inexpensive genotyping techniques. This software will elucidate the complex relationship between drug efficacy and side effects, and multiple interacting genes and environmental factors. Preliminary results, obtained by using simulated data, indicate that it might be feasible to link phenotype to genotype for a list of "candidate genes." The statistical methods are expected to be successful even if the disease mechanism can differ from one person to another. By analyzing and interpreting clinical trial data, the software will match drugs to target populations according to their specific genotype. This will enable pharmaceutical companies to create novel drugs that render maximum effectiveness and have minimum side effects, i.e. the right drug for the right person. PROPOSED COMMERCIAL APPLICATION: The target markets for the research include pharmaceutical companies, CRO'S universities, and government agencies. It has good potential for commercialization because it is expected to help create novel drugs, boost the safety of drug treatments, save substantial resources, and make sense of complex genotype/phenotype relationships in clinical trials context.

描述（申请人的摘要）：软件系统的开发是 提出将结合统计理论、计算机科学算法和 遗传学专业知识，以利用产生的大量数据 人类基因组的研究和廉价基因分型的创建 技术。该软件将阐明药物之间的复杂关系 功效和副作用，以及多种相互作用的基因和环境 因素。通过使用模拟数据获得的初步结果表明 将表型与基因型联系起来以获得“候选者”列表可能是可行的 基因。”即使 疾病机制因人而异。通过分析和 解释临床试验数据，软件将药物与目标相匹配 根据其特定基因型的人群。这将使 制药公司创造新药，最大限度地发挥作用 有效且副作用最小，即对症下药 人。 拟议的商业应用： 研究的目标市场包括制药公司、CRO'S 大学和政府机构。 具有良好的商业化潜力 因为它有望帮助创造新药，提高药物治疗的安全性， 节省大量资源，并理解复杂的基因型/表型关系 在临床试验背景下。